• 1
    Nakamura T, Matsui M, Uchida K, Futatsugi A, Kusakawa S, Matsumoto N, et al. M3 muscarinic acetylcholine receptor plays a critical role in parasympathetic control of salivation in mice. J Physiol 2004; 558: 56175.
  • 2
    Matsui M, Motomura D, Karasawa H, Fujikawa T, Jiang J, Komiya Y, et al. Multiple functional defects in peripheral autonomic organs in mice lacking muscarinic acetylcholine receptor gene for the M3 subtype. Proc Natl Acad Sci U S A 2000; 97: 957984.
  • 3
    Smith PM. Mechanisms of secretion by salivary glands. In: EdgarWM, O'MullaneD, editors. Saliva and oral health. London: BDJ; 1996. p. 925.
  • 4
    Dawson LJ, Allison HE, Stanbury J, Fitzgerald D, Smith PM. Putative anti-muscarinic antibodies cannot be detected in patients with primary Sjogren's syndrome using conventional immunological approaches. Rheumatology (Oxford) 2004; 43: 148895.
  • 5
    Bacman S, Sterin-Borda L, Camusso JJ, Arana R, Hubscher O, Borda E. Circulating antibodies against rat parotid gland M3 muscarinic receptors in primary Sjogren's syndrome. Clin Exp Immunol 1996; 104: 4549.
  • 6
    Beroukas D, Goodfellow R, Hiscock J, Jonsson R, Gordon TP, Waterman SA. Up-regulation of M3-muscarinic receptors in labial salivary gland acini in primary Sjogren's syndrome. Lab Invest 2002; 82: 20310.
  • 7
    Li J, Ha YM, Ku NY, Choi SY, Lee SJ, Oh SB, et al. Inhibitory effects of autoantibodies on the muscarinic receptors in Sjogren's syndrome. Lab Invest 2004; 84: 14308.
  • 8
    Robinson CP, Brayer J, Yamachika S, Esch TR, Peck AB, Stewart CA, et al. Transfer of human serum IgG to nonobese diabetic Igμ null mice reveals a role for autoantibodies in the loss of secretory function of exocrine tissues in Sjogren's syndrome. Proc Natl Acad Sci U S A 1998; 95: 753843.
  • 9
    Waterman SA, Gordon TP, Rischmueller M. Inhibitory effects of muscarinic receptor autoantibodies on parasympathetic neurotransmission in Sjögren's syndrome. Arthritis Rheum 2000; 43: 164754.
  • 10
    Wang F, Jackson MW, Maughan V, Cavill D, Smith AJ, Waterman SA, et al. Passive transfer of Sjögren's syndrome IgG produces the pathophysiology of overactive bladder. Arthritis Rheum 2004; 50: 363745.
  • 11
    Cavill D, Waterman SA, Gordon TP. Antiidiotypic antibodies neutralize autoantibodies that inhibit cholinergic neurotransmission. Arthritis Rheum 2003; 48: 3597602.
  • 12
    Bachmeyer C, Zuber M, Dupont S, Blanche P, Dhote R, Mas JL. Adie syndrome as the initial sign of primary Sjogren syndrome. Am J Ophthalmol 1997; 123: 6912.
  • 13
    Kovacs L, Torok T, Bari F, Keri Z, Kovacs A, Makula E, et al. Impaired microvascular response to cholinergic stimuli in primary Sjogren's syndrome. Ann Rheum Dis 2000; 59: 4853.
  • 14
    Dawson L, Tobin A, Smith P, Gordon T. Antimuscarinic antibodies in Sjögren's syndrome: where are we, and where are we going? [review]. Arthritis Rheum 2005; 52: 298495.
  • 15
    Dawson LJ, Christmas SE, Smith PM. An investigation of interactions between the immune system and stimulus-secretion coupling in mouse submandibular acinar cells: a possible mechanism to account for reduced salivary flow rates associated with the onset of Sjogren's syndrome. Rheumatology (Oxford) 2000; 39: 122633.
  • 16
    Dawson LJ, Caulfield VL, Stanbury JB, Field AE, Christmas SE, Smith PM. Hydroxychloroquine therapy in patients with primary Sjogren's syndrome may improve salivary gland hypofunction by inhibition of glandular cholinesterase. Rheumatology (Oxford) 2005; 44: 44955.
  • 17
    Zoukhri D, Kublin CL. Impaired neurotransmitter release from lacrimal and salivary gland nerves of a murine model of Sjogren's syndrome. Invest Ophthalmol Vis Sci 2001; 42: 92532.
  • 18
    Cavill D, Waterman SA, Gordon TP. Failure to detect antibodies to extracellular loop peptides of the muscarinic M3 receptor in primary Sjogren's syndrome. J Rheumatol 2002; 29: 13424.
  • 19
    Vitali C. Classification criteria for Sjogren's syndrome. Ann Rheum Dis 2003; 62: 945.
  • 20
    Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al, and the European Study Group on Classification Criteria for Sjogren's Syndrome. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61: 5548.
  • 21
    Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, et al. Measurement of protein using bicinchoninic acid (published erratum appears in Anal Biochem 1987;163:279). Anal Biochem 1985; 150: 7685.
  • 22
    Cavill D, Waterman SA, Gordon TP. Antibodies raised against the second extracellular loop of the human muscarinic M3 receptor mimic functional autoantibodies in Sjogren's syndrome. Scand J Immunol 2004; 59: 2616.
  • 23
    Smith PM, Gallacher DV. Acetylcholine- and caffeine-evoked repetitive transient Ca2+-activated K+ and C1− currents in mouse submandibular cells. J Physiol 1992; 449: 10920.
  • 24
    Hann LE, Kelleher RS, Sullivan DA. Influence of culture conditions on the androgen control of secretory component production by acinar cells from the rat lacrimal gland. Invest Ophthalmol Vis Sci 1991; 32: 261021.
  • 25
    Smith PM. Patch-clamp whole-cell pulse protocol measurements using a microcomputer. J Physiol 1992; 446: 72P.
  • 26
    Harmer AR, Smith PM, Gallacher DV. Local and global calcium signals and fluid and electrolyte secretion in mouse submandibular acinar cells. Am J Physiol Gastrointest Liver Physiol 2005; 288: G11824.
  • 27
    Thorn P, Lawrie AM, Smith PM, Gallacher DV, Petersen OH. Ca2+ oscillations in pancreatic acinar cells: spatiotemporal relationships and functional implications. Cell Calcium 1993; 14: 74657.
  • 28
    Bacman S, Berra A, Sterin-Borda L, Borda E. Muscarinic acetylcholine receptor antibodies as a new marker of dry eye Sjogren syndrome. Invest Ophthalmol Vis Sci 2001; 42: 3217.
  • 29
    Bacman S, Perez Leiros C, Sterin-Borda L, Hubscher O, Arana R, Borda E. Autoantibodies against lacrimal gland M3 muscarinic acetylcholine receptors in patients with primary Sjogren's syndrome. Invest Ophthalmol Vis Sci 1998; 39: 1516.
  • 30
    Bacman SR, Berra A, Sterin-Borda L, Borda ES. Human primary Sjogren's syndrome autoantibodies as mediators of nitric oxide release coupled to lacrimal gland muscarinic acetylcholine receptors. Curr Eye Res 1998; 17: 113542.
  • 31
    Gordon TP, Bolstad AI, Rischmueller M, Jonsson R, Waterman SA. Autoantibodies in primary Sjogren's syndrome: new insights into mechanisms of autoantibody diversification and disease pathogenesis. Autoimmunity 2001; 34: 12332.
  • 32
    Kovacs L, Marczinovits I, Gyorgy A, Toth GK, Dorgai L, Pal J, et al. Clinical associations of autoantibodies to human muscarinic acetylcholine receptor 3(213-228) in primary Sjogren's syndrome. Rheumatology (Oxford) 2005; 44: 10215.
  • 33
    Perez Leiros C, Sterin-Borda L, Hubscher O, Arana R, Borda ES. Activation of nitric oxide signaling through muscarinic receptors in submandibular glands by primary Sjogren syndrome antibodies. Clin Immunol 1999; 90: 1905.
  • 34
    Nguyen KH, Brayer J, Cha S, Diggs S, Yasunari U, Hilal G, et al. Evidence for antimuscarinic acetylcholine receptor antibody–mediated secretory dysfunction in NOD mice. Arthritis Rheum 2000; 43: 2297306.
  • 35
    Gao J, Cha S, Jonsson R, Opalko J, Peck AB. Detection of anti-type 3 muscarinic acetylcholine receptor autoantibodies in the sera of Sjogren's syndrome patients by use of a transfected cell line assay. Arthritis Rheum 2004; 50: 261521.
  • 36
    Smith PM. Ins(1,3,4,5)P4 promotes sustained activation of the Ca2+-dependent Cl− current in isolated mouse lacrimal cells. Biochem J 1992; 283: 2730.
  • 37
    Harmer AR, Gallacher DV, Smith PM. Role of Ins(1,4,5)P3, cADP-ribose and nicotinic acid-adenine dinucleotide phosphate in Ca2+ signalling in mouse submandibular acinar cells. Biochem J 2001; 353: 55560.
  • 38
    Scully C. Sjogren's syndrome: clinical and laboratory features, immunopathogenesis, and management. Oral Surg Oral Med Oral Pathol 1986; 62: 51023.
  • 39
    Fox PC, Speight PM. Current concepts of autoimmune exocrinopathy: immunologic mechanisms in the salivary pathology of Sjogren's syndrome. Crit Rev Oral Biol Med 1996; 7: 14458.
  • 40
    Drachman DB. Autonomic “myasthenia”: the case for an autoimmune pathogenesis. J Clin Invest 2003; 111: 7979.
  • 41
    Marczinovits I, Kovacs L, Gyorgy A, Toth GK, Dorgai L, Molnar J, et al. A peptide of human muscarinic acetylcholine receptor 3 is antigenic in primary Sjogren's syndrome. J Autoimmun 2005; 24: 4754.
  • 42
    Goldblatt F, Gordon TP, Waterman SA. Antibody-mediated gastrointestinal dysmotility in scleroderma. Gastroenterology 2002; 123: 114450.
  • 43
    Harmer AR, Gallacher DV, Smith PM. Correlations between the functional integrity of the endoplasmic reticulum and polarized Ca2+ signalling in mouse lacrimal acinar cells: a role for inositol 1,3,4,5-tetrakisphosphate. Biochem J 2002; 367: 13743.
  • 44
    Jahn K, Franke C, Bufler J. Mechanism of block of nicotinic acetylcholine receptor channels by purified IgG from seropositive patients with myasthenia gravis. Neurology 2000; 54: 4749.